Page 323 - Haematologica April 2020

Evaluating Netherlands’ transition from FFP to SD plasma
References
1. Wong MP, Droubatchevskaia N, Chipperfield KM, Wadsworth LD, Ferguson DJ. Guidelines for frozen plasma transfusion. B C Med J. 2007;49(6):311-319.
2. Tinmouth A, Thompson T, Arnold DM, et al. Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions. Transfusion. 2013;53(10):2222-2229.
3. Sanquin Bloed Supply. Vergelijking Q-plas- ma Omniplasma. https://www.sanquin.org/binaries/con- tent/assets/nl/producten-en- diensten/plasmaproducten/vergelijking_q- plasma-omniplasma.pdf (2014, accessed May 23, 2019).
4. Wiersum-OsseltonJC,MiddelburgRA,van der Bom JG, Van TA, Zijlker-Jansen PY, Schipperus MR. Effect of using male-only fresh frozen plasma for TRALI prevention in the Netherlands. Vox Sang. 2010; 99(S):457.
5. Wiersum-Osselton JC, Schipperus MR. Transfusiereacties bij patiënten : hemovigi- lantiemeldingen aan het Landelijk Hemovigilantiebureau over 2003. Ned Tijdschrijft voor Geneeskd. 2005; 149(47):2622-2627.
6. Edel E, Al-Ali HK, Seeger S, Kauschat D, Matthes G. Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience. Transfus Med Hemother. 2010;37(1):13-19.
7. Solheim BG, Seghatchian J. Update on pathogen reduction technology for thera- peutic plasma: an overview. Transfus Apher Sci. 2006;35(1):83-90.
8. Saadah NH, van der Bom JG, Wiersum- Osselton JC, et al. Comparing transfusion reaction risks for various plasma products - an analysis of 7 years of ISTARE haemovig- ilance data. Br J Haematol. 2018; 180(5):727-734.
9. Scully M, Longair I, Flynn M, Berryman J, Machin SJ. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang. 2007;93(2):154-158.
10. Mayr WR. Haemovigilance: are there sig- nificant differences among plasma prod- ucts? Transfus Apher Sci. 2010;43(3):407- 409.
11. Riedler GF, Haycox R, Duggan K, Dakin H. Cost-effectiveness of solvent/detergent- treated fresh-frozen plasma. Vox Sang. 2003;85(2):88-95.
12. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion. 1998; 38(1):102-107.
13. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of sol- vent-detergent treated plasma. Vox Sang. 1998;74(S1):237-239.
14. Hellstern P, Solheim BG. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. Transfus Med Hemother. 2011;38(1):65-70.
15. Pandey S, Vyas GN. Adverse effects of plas- ma transfusion. Transfusion. 2012;52(Suppl 1):65S-79S.
16. Cinqualbre J, Kientz D, Remy E, Huang N, Corash L, Cazenave JP. Comparative effec- tiveness of plasma prepared with amotos- alen-UVA pathogen inactivation and con- ventional plasma for support of liver trans-
plantation. Transfusion. 2015;55(7):1710-
1720.
17. van Hoeven LR, Koopman MM, Koffijberg
H, Roes KC, Janssen MP. Historical time trends in red blood cell usage in the Netherlands. Int J Clin Transfus Med. 2016; (4):67-77.
18. Marietta M, Franchini M, Bindi ML, Picardi F, Ruggeri M, De Silvestro G. Is solvent/detergent plasma better than stan- dard fresh-frozen plasma? A systematic review and an expert consensus document. Blood Transfus. 2016;14(4):277-286.
19. TRIP National Hemovigilance and Biovigilance Office. Transfusie- en trans- plantatiereacties in Patiënten annual report (2016). 10–11. https://www.tripnet.nl/pub- licaties/rapporten/ (accessed May 23, 2019).
20. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482.
21. Liumbruno GM, Catalano L, Piccinini V, Pupella S, Grazzini G. Reduction of the risk of bacterial contamination of blood compo- nents through diversion of the first part of the donation of blood and blood compo- nents. Blood Transfus. 2009;7(2):86-93.
22. Iorio A, Basileo M, Marchesini E, et al. Audit of the clinical use of fresh-frozen plasma in Umbria: Study design and results of the pilot phase. Blood Transfus. 2008;6211-6219.
23. Pahuja S, Sethi N, Singh S, Sharma S, Jain M, Kushwaha S. Concurrent audit of fresh frozen plasma: experience of a tertiary care hospital. Hematology. 2012;17(5):306-310.
haematologica | 2020; 105(4)
1165